Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBT versus flupentixol for auditory verbal hallucinations in borderline personality disorder
NL-OMON48446Phase 4Withdrawn
- Sponsor
- Parnassia Therapeutics
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of flupentixol in borderline personality disorder (BPD) (2 arms), sponsored by Parnassia Therapeutics. Primary endpoint: AVH-related items of the Psychotic Symptom Rating Scales. Planned start Oct 2019; status: withdrawn.
02
Drugs
flupentixol
03
Conditions
borderline personality disorder (BPD)
Beyond the preview
Go deeper on NL-OMON48446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48446.